Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of TRC102 in Combination With Cisplatin and Pemetrexed in Patients With Advanced Solid Tumors / Phase II Study of TRC102 With Pemetrexed in Patients Refractory to Pemetrexed and Cisplatin or Carboplatin

NCT02535312 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT02535312
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02535312 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of TRC102 in Combination With Cisplatin and Pemetrexed in Patients With Advanced Solid Tumors / Phase II Study of TRC102 With Pemetrexed in Patients Refractory to Pemetrexed and Cisplatin or Carboplatin
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
March 8, 2016
Completion date
October 15, 2026
Enrollment
30 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignant solid neoplasm, advanced peritoneal malignant mesothelioma, advanced pleural malignant mesothelioma, recurrent peritoneal malignant mesothelioma, recurrent pleural malignant mesothelioma, refractory malignant solid neoplasm, unresectable solid neoplasm